Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEARL: Partial TACE + Lenvatinib in Unresectable HCC
NCT07827807Phase 2Not yet recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Nov 2026
- Primary completion
- May 2029
01
Overview
A Phase 2 trial of lenvatinib in hepatocellular carcinoma (HCC), sponsored by Chang Gung Memorial Hospital. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07827807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827807.